中国实用内科杂志2014，Vol.34Issue(6)：584-588,5.DOI:10.7504/nk2014050401
咪唑立宾治疗活动性系统性红斑狼疮疗效分析
Clinical efficacy of mizoribine in treatment of active systemic lupus erythematosus
摘要
Abstract
Objective To evaluate the efficacy and safety of mizoribine (MZR) for active systemic lupus erythematosus (SLE) in comparison with mycophenolate mofetil (MMF) and cyclophosphamide (CYC).Methods Ninety patients with active SLE were enrolled between April 2012 and March 2013.Thirty patients were given MZR orally at a dose of 300 mg every other day.Thirty patients were taken MMF at 2 g per day in two divided doses.Thirty patients received 0.5 g CYC intravenously every two weeks.Therapeutic effects and adverse events (AEs) were evaluated at the end of 24-week treatment.Results The overall response rates of MZR,MMF and CYC group were 75.86％,78.58％,and 79.31％ at week 24 respectively.In MZR,MMF and CYC group,34.48 ％,39.29％,and 37.93 ％ patients achieved complete remission respectively.There was no significant difference in the overall response rates or complete remission rates among the three groups.SLEDAI scores,24-hour proteinuria and anti-dsDNA titer significantly decreased in all the three groups.All of the three treatments significantly increased leukocyte counts,hemoglobin levels,platelet counts,and serum complement C3 and CA levels.No significant difference was observed in the parameters above among the three groups.The incidences of AEs in patients treated with MZR or MMF were significantly lower than those in patients treated with CYC.Conclusion MZR is well tolerated and has an effect similar to MMF or CYC in the treatment of active SLE,which may serve as a novel and alternative approach for SLE patients.关键词
咪唑立宾/霉酚酸酯/环磷酰胺/红斑狼疮,系统性Key words
mizoribine / mycophenolate mofetil / cyclophosphamide / lupus erythematosus, systemic分类
医药卫生引用本文复制引用
顾菲,冯学兵,陈纬纬,刘焱,魏华,刘琳,殷松楼,述展云,孙凌云..咪唑立宾治疗活动性系统性红斑狼疮疗效分析[J].中国实用内科杂志,2014,34(6):584-588,5.基金项目
国家自然科学基金青年科学基金项目(81302557) （81302557）
中华医学会临床医学科研专项基金(12040720372) （12040720372）
南京市青年科技人才启动项目(QYK09173) （QYK09173）
